Status:
NOT_YET_RECRUITING
Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia
Lead Sponsor:
Chinese PLA General Hospital
Collaborating Sponsors:
Peking University Third Hospital
Zhengzhou Central Hospital
Conditions:
VAP - Ventilator Associated Pneumonia
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial inf...
Detailed Description
This study investigates the clinical application of bacteriophage therapy in severe infections through a prospective, randomized, multi-center trial targeting ventilator-associated pneumonia (VAP) cau...
Eligibility Criteria
Inclusion
- Diagnosed with ventilator-associated pneumonia (VAP);
- Identified infection with MDR Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa via MROSE evaluation and antimicrobial susceptibility testing (AST) from this or other tertiary hospitals;
- Aged 18 to 85 years;
- Written informed consent obtained from the patient or legal guardian.
Exclusion
- Pregnant or breastfeeding women;
- FiO₂ ≥ 70% or PEEP ≥ 15 cmH₂O;
- Hemodynamic instability (vasopressor dose increased by ≥30% in the last 6 hours or norepinephrine \> 0.5 μg/kg/min);
- Known allergy to phage components.
Key Trial Info
Start Date :
November 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2028
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT07202234
Start Date
November 1 2025
End Date
May 31 2028
Last Update
October 1 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.